西班牙多队列分析:2020年以来早发HIV感染儿童、青少年及年轻成人的临床与免疫病毒学状态
该多中心回顾性队列研究纳入642例西班牙CoRISpe及CoRISpe-FARO队列中早发HIV感染者,描述其2020年以来的临床、病毒学与免疫学结局。81.1%实现病毒学抑制,10.5%经历病毒学失败,52.3%达到CD4/CD8比值≥1。含PI方案与病毒学失败相关,整合酶链转移抑制剂似有保护作用。
要点
- 81.1%实现病毒学抑制,10.5%经历病毒学失败
- 含PI方案与病毒学失败相关,INSTI似有保护作用
- 52.3%达到CD4/CD8比值≥1,晚启动ART与低CD4谷值是免疫恢复不良相关因素
核心结论
- 早期启动ART和针对性干预对优化早发HIV感染者结局至关重要。
- 含PI方案是病毒学失败的危险因素,整合酶链转移抑制剂似有保护作用。
- 青少年和年轻成人需要针对性支持以改善依从性和免疫恢复。
研究设计与样本
- 多中心回顾性队列研究,使用CoRISpe和CoRISpe-FARO队列中642例活跃随访的早发HIV感染者数据。
- 收集人口学、ART史、病毒学抑制(病毒载量≤50 copies/mL)、CD4/CD8比值和CDC免疫分类数据。
- 采用logistic回归识别影响病毒学失败和免疫进展的因素。
主要发现
- 中位年龄24岁,67.6%年龄≥18岁。
- 93.6%经垂直传播感染,ART启动中位年龄1.93岁。
- 分析时99.1%正在接受ART,81.1%实现病毒学抑制,10.5%经历病毒学失败。
- 病毒学失败与含PI方案相关,独立于年龄,并与较低CD4谷值相关。
- 52.3%达到CD4/CD8比值≥1;免疫恢复不良与较晚启动ART和较低CD4谷值相关,尤其在12-18岁青少年和年轻成人中;<12岁儿童97.8%达到CD4计数≥500 cells/mm³。
关键数值与推荐
- 病毒学抑制定义为病毒载量≤50 copies/mL。
- 免疫恢复定义为CD4/CD8比值≥1。
- 病毒学失败与含PI方案相关,整合酶链转移抑制剂似有保护作用。
临床怎么用
- 对早发HIV感染者应尽早启动ART以优化长期结局。
- 含PI方案者需关注病毒学失败风险,可考虑整合酶链转移抑制剂方案。
- 青少年和年轻成人需针对性支持以提高依从性和免疫恢复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: ART has significantly improved survival among children, adolescents and young adults who acquired HIV perinatally or during early childhood (early-life acquired HIV, ELHIV). However, challenges persist, including virological failure (VF) and suboptimal immune recovery. This study aimed to describe clinical, virological and immunological outcomes of ELHIV individuals in Spain since 2020, and to identify factors associated with VF and impaired immune recovery. METHODS: A multicentre, retrospective cohort study was conducted using data from 642 ELHIV individuals actively followed in the CoRISpe and CoRISpe-FARO cohorts. Data included demographics, ART history, virological suppression (viral load ≤50 copies/mL), CD4/CD8 ratio and CDC immunological categories. Logistic regression identified factors influencing VF and immune progression. RESULTS: The median age of participants was 24 years, with 67.6% aged ≥18. Most (93.6%) acquired HIV via vertical transmission, with ART initiated at a median age of 1.93 years. At the time of analysis, 99.1% were on ART. Although 81.1% achieved virological suppression, 10.5% experienced VF, associated with PI-based regimens, independent of age, and a lower CD4 nadir. Immune recovery, defined as a CD4/CD8 ratio ≥1, was achieved by 52.3%. Impaired recovery was linked to older age at ART initiation and lower CD4 nadir, particularly among adolescents (12-18 years) and young adults. Children (<12 years) showed better immune profiles, with 97.8% achieving CD4 counts ≥500 cells/mm³. CONCLUSIONS: Early ART initiation and tailored interventions are essential to optimize outcomes in ELHIV populations. PI-based regimens were a risk factor for VF, whereas integrase strand transfer inhibitors appeared protective. Adolescents and young adults require targeted support to improve adherence and immune recovery, aligning with UNAIDS goals.
引用
- Tarancon-Diez L, Lazaro-Martin B, Goicoechea-Martínez J, et al. Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020. J Antimicrob Chemother. 2026. PMID: 41808664. doi:10.1093/jac/dkag079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。